Charles Schwab Investment Management Inc Replimune Group, Inc. Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 418,664 shares of REPL stock, worth $4.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

418,664

Previous 401,942 4.16%

Holding current value

$4.2 Million

Previous $3.39 Million 0.94%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$6.87 - $9.31 $114,880 - $155,681	16,722 Added 4.16%	418,664 $3.42 Million
Q4 2023 Feb 06, 2024	BUY	$6.75 - $16.18 $159,516 - $382,365	23,632 Added 6.25%	401,942 $3.39 Million
Q3 2023 Nov 08, 2023	BUY	$15.96 - $22.18 $1.49 Million - $2.07 Million	93,364 Added 32.77%	378,310 $6.47 Million
Q2 2023 Aug 09, 2023	SELL	$15.65 - $24.1 $183,214 - $282,138	-11,707 Reduced 3.95%	284,946 $6.62 Million
Q1 2023 May 11, 2023	BUY	$17.48 - $29.09 $648,088 - $1.08 Million	37,076 Added 14.28%	296,653 $5.24 Million

Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $125,389 - $204,775	7,337 Added 2.91%	259,577 $7.06 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $659,989 - $894,793	42,307 Added 20.15%	252,240 $4.36 Million
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $78,774 - $118,161	-5,914 Reduced 2.74%	209,933 $3.67 Million
Q1 2022 May 13, 2022	BUY	$15.24 - $29.75 $105,963 - $206,851	6,953 Added 3.33%	215,847 $3.67 Million
Q4 2021 Feb 11, 2022	BUY	$25.43 - $34.25 $92,514 - $124,601	3,638 Added 1.77%	208,894 $5.66 Million
Q3 2021 Nov 16, 2021	BUY	$28.98 - $39.54 $694,418 - $947,457	23,962 Added 13.22%	205,256 $6.08 Million
Q2 2021 Aug 16, 2021	BUY	$28.5 - $39.37 $215,887 - $298,227	7,575 Added 4.36%	181,294 $6.97 Million
Q1 2021 May 17, 2021	BUY	$30.22 - $45.57 $262,611 - $396,003	8,690 Added 5.27%	173,719 $5.3 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $687,892 - $1.54 Million	29,272 Added 21.56%	165,029 $6.3 Million
Q3 2020 Nov 13, 2020	BUY	$18.85 - $27.0 $1.79 Million - $2.56 Million	94,999 Added 233.08%	135,757 $3.13 Million
Q2 2020 Aug 14, 2020	BUY	$9.76 - $25.95 $80,656 - $214,450	8,264 Added 25.43%	40,758 $1.01 Million
Q1 2020 May 15, 2020	BUY	$8.9 - $19.08 $11,427 - $24,498	1,284 Added 4.11%	32,494 $324,000
Q4 2019 Feb 07, 2020	BUY	$11.61 - $17.21 $41,192 - $61,061	3,548 Added 12.83%	31,210 $448,000
Q1 2019 May 14, 2019	BUY	$10.26 - $16.24 $138,530 - $219,272	13,502 Added 95.35%	27,662 $422,000
Q3 2018 Nov 13, 2018	BUY	$14.99 - $22.14 $212,258 - $313,502	14,160 New	14,160 $228,000

Others Institutions Holding REPL

# of Institutions

151

Shares Held

66M

Call Options Held

79.4K

Put Options Held

102K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $495M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Replimune Group, Inc. Transaction History